Default company panoramic image
Logo

ProNAi Therapeutics, Inc.

ProNAi is dedicated to commercializing a new class of therapies that target DNA to treat patients with cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Plymouth Township, MI, USA
  • Currency USD
  • Founded December 2004
  • Employees 6
  • Website pronai.com

Company Summary

ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to develop novel therapeutic approaches for proliferative diseases. The company was founded in 2004 by pharmaceutical scientists who have substantial experience in the area of nucleic acid research. The founders leveraged their experience to design a new class of therapies. ProNAi’s most advanced product, PNT2258, is currently in clinical trials.

Team

  • Default avatar
    Richard Messmann, MD
    Chief Medical Officer

    Dr. Messmann has extensive clinical and commercial experience as a medical oncologist and drug-development physician. He had fellowship training at the National Cancer Institute (NCI) prior to becoming deputy associate director of the NCI Developmental Therapeutics Program. He has also served as VP of Medical Affairs for Endocyte, Director of Cancer Research for the Great Lakes Cancer Institute at Michigan State University.

  • Default avatar
    Mina Sooch, MBA
    President and CEO

    Ms. Sooch brings with her over twenty years of pharmaceutical and healthcare experiences as an entrepreneur and operator, strategy & finance advisor, and venture capitalist. Prior to venture capital, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity com

  • Default avatar
    Wendi Rodrigueza, PhD
    VP of Product Development

    Dr. Rodrigueza, whose therapeutic research expertise includes cardiovascular disease, oncology, diabetes and metabolic diseases, joins ProNAi after most recently serving at Novartis Institute of Biomedical Research, Inc. (NIBRI) as Director, Product Management, Cardiovascular Disease Area. Prior to NIBRI, Dr. Rodrigueza held numerous senior research positions at both CuraGen and Esperion Therapeutics.

Advisors

  • Default avatar
    Joscelyn Boucher, Honigman Miller Schwartz and Cohn LLP
    Lawyer
    Unconfirmed
    Default avatar
    Doug Burlingham
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Apjohn Ventures
    Unconfirmed
    Default avatar
    Grand Angels
    Unconfirmed
    Default avatar
    Biosciences Research Commercialization Center
    Unconfirmed